SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 34.50+2.7%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: bob zagorin5/12/2005 12:44:45 PM
   of 17367
 
XOMA "neutral," estimates revised

Thursday, May 12, 2005 7:41:59 AM ET
First Albany

NEW YORK, May 12 (newratings.com) - Analyst David Webber of First Albany maintains his "neutral" rating on XOMA Ltd (XOMA.NAS), while revising his estimates for the company.

In a research note published this morning, the analyst mentions that the company reported its 1Q05 EPS, excluding a one-time gain, ahead of the estimates and the consensus. XOMA intends to build a revenue stream from contract manufacturing, which has increased significantly from the previous year's levels, the analyst says. The EPS estimate for FY05 has been raised from -$0.46 to -$0.38, while the EPS estimate for FY06 has been reduced from -$0.28 to -$0.29.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext